Yorvipath (palopegteriparatide) / Ascendis, Teijin, Specialised Therap, Royalty - LARVOL DELTA

Hypoparathyroidism: translating science from the laboratory to the clinic. (PubMed, Lancet Diabetes Endocrinol) - "PTH analogues with extended action (eg, palopegteriparatide, eneboparatide, and canvuparatide) show sustained activation of PTH receptors with reduced requirements for active forms of vitamin D and calcium supplements. Calcilytics (eg, encaleret) normalise calcium-sensing receptor (CaSR) hyperactivation in patients with autosomal dominant hypocalcaemia type 1 and have the potential for broader application in other forms of hypoparathyroidism...Translational research is redefining the future of hypoparathyroidism management. Developments in receptor-targeted therapies, long-acting PTH analogues, negative allosteric modulators of CaSR, and regenerative approaches reflects a shift towards restoring mineral homoeostasis to a more physiological state."

Journal • Review • Endocrine Disorders • Hypoparathyroidism • Transplantation

Palopegteriparatide in a cohort pediatric patients with primary hypoparathyreoidism - a case series (ESPE 2026) - No abstract available

Clinical • Pediatrics

Pendopharm…in collaboration with Ascendis Pharma A/S…announced that Canada’s Drug Agency, or CDA-AMC, has recommended that Yorvipath (palopegteriparatide injection) be reimbursed with conditions by participating public drug plans for eligible adults with chronic hypoparathyroidism that are not adequately controlled with conventional therapy (GlobeNewswire) - "The CDA-AMC recommendation represents an important step in the Canadian public reimbursement process. The CDA-AMC review considered evidence from the Phase 3 PaTHway clinical trial, which evaluated palopegteriparatide in adults with chronic hypoparathyroidism."

Reimbursement • Endocrine Disorders • Hypoparathyroidism

Real-world data for effectiveness and safety of palopegteriparatide in patients with chronic hypoparathyroidism: the PaTH REAL study. (PubMed, Eur J Endocrinol) - P | "In a real-world setting, palopegteriparatide effectively normalizes calcium-phosphate homeostasis, reduces hypercalciuria, and substantially decreases reliance on conventional therapy, with a favorable safety profile."

Journal • Real-world evidence • Endocrine Disorders • Hypoparathyroidism • Metabolic Disorders • Nephrology • Renal Disease

Methodological Differences Limit the Feasibility of an Indirect Treatment Comparison Between the Phase III CALYPSO (Eneboparatide) and PaTHway (Palopegteriparatide) Trials in Chronic Hypoparathyroidism (ASBMR 2026) - No abstract available

Late-breaking abstract • P3 data • Endocrine Disorders • Hypoparathyroidism

Palopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update. (PubMed, JBMR Plus) - "These early observations highlight the effectiveness of palopegteriparatide in patients with APECED, enabling the discontinuation of oral calcium and active vitamin D supplements. They also highlight the question of whether etiology-specific differences in responsiveness may influence dose requirements and calcemic stability."

Journal • Candidiasis • Endocrine Disorders • Gastrointestinal Disorder • Hypoparathyroidism • Immunology • Metabolic Disorders • Nephrology • Orthopedics • Renal Disease

The impact of parathyroid hormone replacement with palopegteriparatide on synthesis of 1,25-dihydroxy vitamin D in hypoparathyroidism. (PubMed, Expert Rev Clin Pharmacol) - "Thus, ensuring formation of 1,25(OH)2D should be a key outcome of interest in drug development of PTH replacement therapies. Data from clinical trials demonstrate active PTH released from palopegteriparatide interacts with PTH1R to ensure adequate 1,25(OH)2D synthesis, enabling independence from active vitamin D analogues, and confirms its position as a PTH replacement therapy."

Journal • Endocrine Disorders • Hypoparathyroidism

A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH (Palopegteriparatide) (clinicaltrials.gov) - P=N/A | N=10 | Recruiting | Sponsor: Ascendis Pharma A/S | Trial completion date: Jan 2028 ➔ Aug 2027 | Trial primary completion date: Jan 2028 ➔ Aug 2027

Trial completion date • Trial primary completion date • Endocrine Disorders • Hypoparathyroidism

Long-Term Effects of Palopegteriparatide on BMD and TBS in Adults With Chronic Hypoparathyroidism: Pooled Results From the PaTH Forward and PaTHway Trials (ASBMR 2026) - No abstract available

Clinical • Endocrine Disorders • Hypoparathyroidism

Hypoparathyroidism: Understanding the Impact of Palopegteriparatide on Patients’ Health Related Quality of Life, Functioning and Well-being (ASBMR 2026) - No abstract available

Clinical • HEOR • Endocrine Disorders • Hypoparathyroidism

Osteoporosis Management in a Patient with Chronic Hypoparathyroidism on Palopegteriparatide: Challenges and Considerations (ASBMR 2026) - No abstract available

Clinical • Endocrine Disorders • Hypoparathyroidism • Osteoporosis • Rheumatology

A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism (clinicaltrials.gov) - P3 | N=12 | Recruiting | Sponsor: Ascendis Pharma A/S

New P3 trial • Endocrine Disorders • Hypoparathyroidism

Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism. (PubMed, J Endocr Soc) - "Palopegteriparatide provided continuous exposure to active PTH within the physiological range. The expected pharmacodynamic effects of continuous PTH exposure on serum and urine chemistries were consistent with the efficacy and safety of palopegteriparatide demonstrated in the published PaTH Forward and PaTHway clinical trials."

Journal • PK/PD data • Endocrine Disorders • Hypoparathyroidism

Clinical Characteristics, Treatment Patterns, and Complications in Permanent Hypoparathyroidism: A Large Retrospective Cross-Sectional Study. (PubMed, Calcif Tissue Int) - "Patients received calcium, calcitriol, thiazide diuretics, cholecalciferol, teriparatide, or palopegteriparatide...Additionally, in univariable analyses, high-dose calcitriol was associated with nephrolithiasis/nephrocalcinosis and high-dose calcium with BGC (p < 0.05). In conclusion, HypoPT-related complications were associated with hyperphosphatemia, hypercalciuria, undetectable PTH, and high-dose conventional treatment, underscoring the need for better treatments and future studies to determine whether PTH-replacement therapy reduces complication risks."

Journal • Observational data • Retrospective data • Cataract • Endocrine Disorders • Hypoparathyroidism • Metabolic Disorders • Nephrology • Ophthalmology • Renal Calculi • Renal Disease • Thyroid Gland Carcinoma

Case Report: Palopegteriparatide as a novel therapeutic option in pediatric autosomal dominant hypocalcemia type 1. (PubMed, Front Endocrinol (Lausanne)) - "This case demonstrates that palopegteriparatide may be a valuable therapeutic option in pediatric patients with ADH1 when conventional therapy fails to provide adequate control and while targeted therapies directed at the mutated CASR are not yet available. Carefully titrated PTH-based therapy can improve symptoms and mineral homeostasis, highlighting the need for further studies on its long-term safety and efficacy in children."

Journal • Cataract • CNS Disorders • Endocrine Disorders • Epilepsy • Genetic Disorders • Hypoparathyroidism • Metabolic Disorders • Nephrology • Ophthalmology • Pediatrics • Renal Disease • CASR

Palopegteriparatide Enhances Work Functioning and Productivity in Employed Adults with Chronic Hypoparathyroidism: 156-Week Results from the Pathway Trial (ENDO 2026) - "Palopegteriparatide treatment led to early improvements in work functioning and productivity in employed adults with chronic hypoparathyroidism. Benefits were observed across all WLQ-25 domains and sustained over three years. These findings support the long-term functional and potential economic value of palopegteriparatide treatment for adults with chronic hypoparathyroidism."

Clinical • Endocrine Disorders • Hypoparathyroidism

Double Gene Defects in A Young Woman with Severe Hypoparathyroidism (ENDO 2026) - "Two intracellular pathways disturbing parathyroid function may have accelerated development of complications like nephrocalcinosis and brain calcification. Treatment with palopegteriparatide led to improved symptoms and quality of life with reduced Ca and calcitriol intake, which may lower risks of renal complications from hypoparathyroidism."

Clinical • Chronic Kidney Disease • CNS Disorders • Depression • Endocrine Disorders • Epilepsy • Genetic Disorders • Hepatology • Hypoparathyroidism • Metabolic Disorders • Mood Disorders • Movement Disorders • Nephrology • Post-traumatic Stress Disorder • Renal Disease • ATP7B

Reversing the Renal Burden: A Systematic Review and Meta-Analysis of Long-Term eGFR Recovery and Safety Outcomes with Palopegteriparatide in Chronic Hypoparathyroidism (ENDO 2026) - "This significant finding supports not only the safety, but the beneficial renal effects of palopegteriparatide in the treatment of chronic hypoparathyroidism. Larger comparative studies with standardized renal outcome reporting are needed to validate this outcome."

Retrospective data • Review • Endocrine Disorders • Hypoparathyroidism

Post-Gastric Bypass Hypoglycemia (PGBH) Amplified by Palopegteriparatide Therapy. (ENDO 2026) - "Case highlights a potential interaction between PTH-analogues and insulin regulation, and it is suggestive that pharmacotherapy directed towards selective calcium channel inhibition may represent a future avenue to modulate postprandial glycemic control for these patients."

Bariatric surgery • Endocrine Disorders • Gastrointestinal Disorder • Hypoglycemia • Hypoparathyroidism • Movement Disorders • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma

A Complicated Course to Cure: Incidental Papillary Thyroid Microcarcinoma and Severe Hypoparathyroidism in Graves' Disease (ENDO 2026) - "Case Presentation: A 46-year-old woman with Graves' disease, previously complicated by thyroid storm, was managed with methimazole after definitive radioactive iodine therapy was not completed due to loss to follow up. This case underscores the increased risk of papillary thyroid carcinoma in patients with Graves' disease, even in the absence of nodules on imaging. It also highlights the morbidity of permanent hypoparathyroidism following thyroidectomy and demonstrates the role of palopegteriparatide in achieving calcium stability when standard supplementation is insufficient."

Endocrine Disorders • Grave’s Disease • Hypoparathyroidism • Oncology • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma • TG

Real World Adverse Events Associated with Palopegteriparatide- A Pharmacovigilance Study (ENDO 2026) - "These findings align with its mechanism of sustained parathyroid hormone exposure and underscore the importance of ongoing pharmacovigilance to monitor for potential long term effects and rare adverse events. Continued post marketing surveillance is needed to further characterize its long term safety and associated clinical outcomes across diverse patient populations, ensuring an optimal benefit risk assessment as its clinical use expands."

Adverse events • Clinical • Real-world • Real-world evidence • Endocrine Disorders • Hypoparathyroidism • Metabolic Disorders • Musculoskeletal Pain • Pruritus

Palopegteriparatide Treatment in Adults with Hypoparathyroidism: Final Results of the Phase 3 PaTHway Trial (ENDO 2026) - "Palopegteriparatide demonstrated durable safety and efficacy in adults with hypoparathyroidism, sustaining normocalcemia, enabling independence from conventional therapy, and improving multiple PRO domains for participants through Week 182."

Clinical • P3 data • Endocrine Disorders • Hypoparathyroidism

Baseline eGFR predicts palopegteriparatide maintenance dose in chronic hypoparathyroidism (ERA 2026) - "Ectopic calcifications may further identify patients maintained on lower doses and warrant longitudinal confirmation. Conventional therapy was substantially reduced, phosphate homeostasis improved, and overall kidney function remained stable during Yorvipath treatment."

Clinical • Chronic Kidney Disease • Endocrine Disorders • Hypoparathyroidism

eGFR trajectories after transition from rhPTH(1-84) to palopegteriparatide in chronic hypoparathyroidism: a clinical practice cohort (ERA 2026) - "Importantly, patients with baseline CKD showed an increase in eGFR after transition to Palopegteriparatide, while non-CKD patients maintained stable eGFR. In rhPTH(1-84) -exposed patients, Palopegteriparatide was associated with further optimization of mineral management—near-complete withdrawal of conventional supplementation and additional phosphate improvement—suggesting incremental therapeutic benefit beyond rhPTH(1-84) in selected patients."

Clinical • Chronic Kidney Disease • Endocrine Disorders • Hypoparathyroidism

Hypoparathyroidism Post Thyroidectomy: Prevention, Evaluation, Management, and Application of Recent Guidelines. (PubMed, Thyroid) - "Postsurgical HypoPT remains a significant complication of thyroid surgery; however, its risk can be mitigated by careful preoperative assessment and surgical technique. While conventional therapy continues to be the mainstay of treatment, the advent of PTH replacement therapies offers promising alternatives for patients with refractory HypoPT."

Journal • Review • Endocrine Disorders • Hypoparathyroidism